

REFERENCES for the AccuCardia ELISA Test System

1. Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. *J Am Coll Cardiol*. 2012;60:S1-S49.
2. World Health Organization. Fact sheet N°317, <http://www.who.int/mediacentre/factsheets/fs317/en/> (accessed July 2014).
3. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva, 2011.
4. World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva, 2011.
5. Million Hearts: About Disease and Stroke Fact Sheet. <http://millionhearts.hhs.gov/about/ds/cost-consequences.html> (accessed July 2015).
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352:1658-1695.
7. Hademenous GJ, Massouf TF. Biophysical mechanisms of stroke. *Stroke*. 1997;28:2067-2077.
8. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation*. 1995;92:1355-1374.
9. American Heart Association. A Public Health Action Plan to Prevent Heart Disease and Stroke. http://www.cdc.gov/dhds/action_plan/pdfs/action_plan_full.pdf (accessed July 2015).
10. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. *Annu Rev Biochem*. 2008;77:495-520.
11. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: Roles as biological effectors and biomarkers. *Circulation*. 2010;122:2183-2200.
12. Karabina SA, Gora S, Atout R, Ninio E. Extracellular phospholipases in atherosclerosis. *Biochimie*. 2010;92:594-600.
13. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. *Eur Heart J*. 2012;33:2899-2909.
14. Balsinde J, Balboa MA, Inseñe PA, Dennis EA. Regulation and inhibition of phospholipase A2. *Annu Rev Pharmacol Toxicol*. 1999;39:175-189.
15. Kudo I, Murakami M. Phospholipase A2 enzymes. *Prostaglandins Other Lipid Mediat*. 2002; 68-69:3-58.
16. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. *Biochim Biophys Acta*. 2006;1761:1246-1259.
17. Ivandic B, Castellini LW, Wang X-P, Qiao J-H, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, Beer MCD, Beer FD, Lusis AJ. Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIA phospholipase A2. *Arterioscler Thromb Vasc Biol*. 1999;19:1284-1290.
18. Hurt-Camejo E, Sartipy P, Peilot H, Rosengren B, Wiklund O, & Camejo G. (2003). Phospholipase A2 in the pathogenesis of cardiovascular disease. *Membrane Lipid Signaling in Aging and Age-Related Disease*, 12, 177.
19. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. *Circulation*. 1999;100:1280-1284.
20. Koenig W, Vossen CY, Ziad M, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. *Eur Heart J*. 2009;30:2742-2748.
21. Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. *Circulation*. 2012;125:757-766, 2012.
22. Xin H, Chen ZY, Lv XB, Liu S, Lian ZX, et al. Serum secretory phospholipase A2-IIA (sPLA2-IIA) levels in patients surviving acute myocardial infarction. *Eur Rev Med Pharmacol Sci*. 2013;17:999-1004.
23. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. *Arterioscler Thromb Vasc Biol*. 2007;27(5):1177-1183.
24. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJP, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM. Oxidation-specific biomarkers, Lipoprotein(a) and risk of fatal and nonfatal coronary events. *JACC*. 2010;56(12):946-955.
25. Simon T et al., European Society of Cardiology Meeting, 2008, p. 1317.
26. Simon T et al., European Society of Cardiology Meeting, 2008, p. 5109.
27. Mallat Z, Steg G, Benessiano J, Tanguy ML, Fox KA, Collet JP, Dabbous OH, Henry P, Carruthers KF, Dauphin A, Arguelles CS, Masliah J, Hugel B, Montalescot G, Freyssinet JM, Asselain B, and Tedgui A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. *J Am Coll Cardiol*. 2005;46(7):1249-1257.
28. O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SF, Braunwald E, Tedgui A, Sabatine MS. Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease. *Clinical Chemistry*. 2011;57(9):1311-1317.
29. Lind L, Simon T, Johansson L, Kotti S, Hansen T, Machecourt J, Ninio E, Tedgui A, Danchin N, Ahlstrom H, Mallat Z. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. *European Heart Journal*. 2012;33(23):2946-2954.